36
Participants
Start Date
September 2, 2021
Primary Completion Date
September 6, 2024
Study Completion Date
January 17, 2025
Surufatinib
Surufatinib 300 mg oral once daily
Kyushu University Hospital, Fukuoka
Fukuoka Sanno Hospital, Fukuoka
Kagawa University Hospital, Kagawa
National Cancer Centre Hospital East, Kashiwa-shi
Kyoto University Hospital, Kyoto
Kyorin University Hospital, Mitaka
Aichi Cancer Centre, Nagoya
Kansia Electric Power Hospital, Osaka
Hokkaido University Hospital, Sapporo
Tohoku University Hospital, Sendai
National Cancer Centre Hospital, Tokyo
Yokohama City University Hospital, Yokohama
Lead Sponsor
Hutchmed
INDUSTRY